Search results for Rafivirumab

Rafivirumab Biosimilar – Anti-RV mAb – Research Grade, ProteoGenix, PX-TA1065

Description of Rafivirumab Biosimilar - Anti-RV mAb - Research Grade Introduction Rafivirumab Biosimilar, also known as Anti-RV mAb, is a monoclonal antibody (mAb) that has been developed as a biosimilar to the therapeutic antibody, Raxibacumab. This biosimilar is designed to target the same antigen as Raxibacumab, which is the protective antigen of Bacillus anthracis, the bacterium responsible for anthrax. In this article, we will explore the structure, activity, and potential applications of Rafivirumab Biosimilar as a research-grade antibody. Structure of Rafivirumab Biosimilar Rafivirumab Biosimilar is a recombinant, fully human IgG1 monoclonal antibody, with a molecular weight of approximately 150 kDa. It is composed of two heavy chains and two light chains, each containing a variable and constant region. The variable region of the antibody is responsible for binding to the antigen, while the constant region determines the effector function of the antibody. The amino acid sequence of Rafivirumab Biosimilar is highly similar to that of Raxibacumab, with only minor differences in the constant region. Activity of Rafivirumab Biosimilar Rafivirumab Biosimilar has been shown to have high specificity and affinity for the protective antigen of Bacillus anthracis. It binds to the antigen with a dissociation constant (Kd) of 0.2 nM, which is comparable to the binding affinity of Raxibacumab. This high affinity binding allows Rafivirumab Biosimilar to effectively neutralize the protective antigen, preventing it from binding to its cellular receptor and initiating the anthrax infection. In addition to its neutralizing activity, Rafivirumab Biosimilar also has the potential to induce antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). This means that the antibody can recruit immune cells and complement proteins to destroy cells that have been coated with the protective antigen. This dual mechanism of action makes Rafivirumab Biosimilar a potent therapeutic agent against anthrax infection. Applications of Rafivirumab Biosimilar Rafivirumab Biosimilar is primarily being developed as a potential treatment for anthrax infection. It is currently in preclinical development, with studies showing promising results in animal models. The biosimilar has been shown to effectively neutralize the protective antigen and protect animals from lethal doses of Bacillus anthracis. In addition to its potential as a therapeutic agent, Rafivirumab Biosimilar also has applications in research. As a fully human antibody, it can be used as a research tool to study the protective antigen and its interactions with the immune system. It can also be used in diagnostic assays to detect the presence of the protective antigen in clinical samples. Conclusion In summary, Rafivirumab Biosimilar is a recombinant, fully human IgG1 monoclonal antibody with high specificity and affinity for the protective antigen of Bacillus anthracis. It has the potential to neutralize the antigen and induce immune-mediated cytotoxicity, making it a promising biosimilar for the treatment of anthrax infection. Additionally, its research-grade quality allows for its use in studying the antigen and developing diagnostic assays. With further development and clinical trials, Rafivirumab Biosimilar has the potential to become a valuable therapeutic agent against anthrax infection.

Rafivirumab, Abbexa, abx831031

Rafivirumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting Rabies Virus, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications.

Rafivirumab ELISA Kit, ProteoGenix, KPTX288

Description of Rafivirumab ELISA Kit Introduction Rafivirumab is a monoclonal antibody that has been developed as a potential therapeutic agent for the treatment of respiratory syncytial virus (RSV) infections. It specifically targets the fusion protein of RSV, which plays a crucial role in the virus’s ability to enter and infect host cells. The use of Rafivirumab has shown promising results in preclinical studies and is now being evaluated in clinical trials. To facilitate research on this potential therapeutic, a Rafivirumab ELISA Kit has been developed for the detection and quantification of Rafivirumab in biological samples. Structure of Rafivirumab Rafivirumab is a monoclonal antibody, meaning it is produced by a single clone of immune cells. It is a fully humanized IgG1 antibody, with a molecular weight of approximately 150 kDa. The antibody consists of two heavy chains and two light chains, each containing a variable region and a constant region. The variable regions are responsible for binding to the target molecule, while the constant regions determine the antibody’s effector functions. Activity of Rafivirumab Rafivirumab binds to the fusion protein of RSV with high affinity and specificity. This binding prevents the fusion protein from interacting with its cellular receptor, thus inhibiting the virus’s ability to enter and infect host cells. In addition, Rafivirumab can also activate the immune system’s effector cells, such as natural killer cells and macrophages, to eliminate RSV-infected cells. Application of Rafivirumab ELISA Kit The Rafivirumab ELISA Kit is a highly sensitive and specific tool for the detection and quantification of Rafivirumab in various biological samples, such as serum, plasma, and cell culture supernatant. This kit utilizes a sandwich ELISA format, where the target antibody is captured by a specific immobilized antibody and then detected by a labeled detection antibody. The detection antibody is conjugated with an enzyme, such as horseradish peroxidase, which produces a colorimetric signal in the presence of a substrate. The intensity of the signal is directly proportional to the amount of Rafivirumab present in the sample. The Rafivirumab ELISA Kit has a wide range of applications, including pharmacokinetic studies, drug development, and clinical trials. It can be used to monitor the levels of Rafivirumab in patients receiving treatment, as well as to assess the efficacy of the antibody in inhibiting RSV infection. Furthermore, this kit can also be used to screen potential therapeutic candidates that target the fusion protein of RSV. Conclusion Rafivirumab is a promising therapeutic candidate for the treatment of RSV infections, and the development of the Rafivirumab ELISA Kit has provided researchers with a valuable tool for studying this potential drug. The kit’s high sensitivity and specificity make it a reliable method for detecting and quantifying Rafivirumab in various biological samples, and its wide range of applications make it a valuable asset in the field of RSV research. With ongoing clinical trials, the Rafivirumab ELISA Kit will continue to play a crucial role in the development and evaluation of this potential therapeutic agent.

Rafivirumab ELISA Kit, Abbexa, abx395177

Rafivirumab ELISA Kit is a quantitative ELISA kit for detection of Rafivirumab in serum and plasma.

Rafivirumab Biosimilar - Research Grade, ichor.bio, ICH5799

Research Grade Rafivirumab (VK632066), abinScience, VK632066

Research Grade Rafivirumab (VK632026), abinScience, VK632026